<DOC>
	<DOCNO>NCT00137813</DOCNO>
	<brief_summary>The purpose study determine effect ( good bad ) bevacizumab ( Avastin ) docetaxel ( Taxotere ) , use combination , metastatic gastric esophageal cancer .</brief_summary>
	<brief_title>Avastin Taxotere Esophagogastric Cancer</brief_title>
	<detailed_description>Bevacizumab administer intravenously outpatient clinic week , every week . Docetaxel also administer intravenously outpatient clinic week three four week . Blood test vital sign perform weekly . After first eight week therapy CT scan perform determine ass progress disease . If therapy continue , radiological procedure perform week 16 every 8 week thereafter . Treatment give minimum 8 week , long patient experience unacceptable side effect . Chemotherapy continue year half long cancer respond unacceptable side effect .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm , unresectable metastatic stage IV esophageal gastric carcinoma Measurable disease great equal 1cm spiral compute tomography ( CT ) scan great equal 2cm radiographic technique ECOG performance status 02 One prior chemotherapy metastatic disease permit White blood cell count great equal 3,000/mm Absolute neutrophil count great equal 1,500/mm3 Platelet count great equal 100,000/mm3 Hemoglobin great equal 8.0g/dl Creatinine less 2.0mg/dL Total bilirubin le 1.9mg/dL Pregnant lactate woman History evidence central nervous system ( CNS ) disease Other active malignancy nonmelanoma skin cancer insitu cervical cancer History severe hypersensitivity docetaxel , bevacizumab drug formulate polysorbate 80 . Current , recent plan treatment standard chemotherapy , radiation therapy another experimental therapy . History disease metabolic dysfunction . Serious , nonhealing wound , ulcer , bone fracture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>AvaTax</keyword>
	<keyword>Metastatic Esophagogastric Cancer</keyword>
</DOC>